
$15m supports first oral therapy to restore gut lymphatic function
Seaport Therapeutics has received an award of up to $15 million to advance its GlyphCele, from the Advanced Research Projects Agency for Health (ARPA-H), in collaboration with the Monash Institute of Pharmaceutical Sciences (MIPS). GlyphCele is an investigational Glyphed oral prodrug of the COX-2 inhibitor celecoxib, which is designed to… Read More

